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Platelet Activation and Clopidogrel Effects on ADP-Induced Platelet
Activation in Cats with or without the A31P Mutation in MYBPC3
R.H.L. Li, J.A. Stern, V. Ho, F. Tablin†, and S.P. Harris†
Background: Clopidogrel is commonly prescribed to cats with perceived increased risk of thromboembolic events, but lit-
tle information exists regarding its antiplatelet effects.
Objective: To determine effects of clopidogrel on platelet responsiveness in cats with or without the A31P mutation in the
MYBPC3 gene. A secondary aim was to characterize variability in feline platelet responses to clopidogrel.
Animals: Fourteen healthy cats from a Maine Coon/outbred mixed Domestic cat colony: 8 cats homozygous for A31P
mutation in the MYPBC3 gene and 6 wild-type cats without the A31P mutation.
Methods: Ex vivo study. All cats received clopidogrel (18.75 mg PO q24h) for 14 days. Before and after clopidogrel treat-
ment, adenosine diphosphate (ADP)-induced P-selectin expression was evaluated. ADP- and thrombin-induced platelet aggre-
gation was measured by optical aggregometry (OA). Platelet pVASP and ADP receptor response index (ARRI) were
measured by Western blot analysis.
Results: Platelet activation from cats with the A31P mutation was significantly (P = .0095) increased [35.55% (18.58–
48.55) to 58.90% (24.85–69.90)], in response to ADP. Clopidogrel treatment attenuated ADP-induced P-selectin expression
and platelet aggregation. ADP- and PGE1-treated platelets had a similar level of pVASP as PGE1-treated platelets after clopi-
dogrel treatment. Clopidogrel administration resulted in significantly lower ARRI [24.13% (12.46–35.50) to 11.30% (7.383
to 23.27)] (P = .017). Two of 13 cats were nonresponders based on OA and flow cytometry.
Conclusion and Clinical Importance: Clopidogrel is effective at attenuating platelet activation and aggregation in some
cats. Cats with A31P mutation had increased platelet activation relative to the variable response seen in wild-type cats.
Key words: Cat; Hypertrophic cardiomyopathy; Platelet hyper-reactivity; Thromboembolism.
ATE is a life-threatening complication associatedwith HCM in cats. Thrombi in left atrial appen-
dages (LAA) of cats can embolize to peripheral and
central arteries causing tissue ischemia, ischemic reper-
fusion injury, and sudden death.1–3 Despite recent
advances in thrombosis research, the underlying role of
platelets in the pathophysiology of ATE in cats remains
poorly understood.
In people, platelet activation and increased P-selectin
expression are associated with myocardial inflammation,
myocardial infarction, and cardiomyopathy.4–6 Platelet
reactivity predicts thromboembolic events associated
with myocardial infarct and coronary stent implanta-
tion.7–9 Altered platelet function occurs in cats with
HCM.10,11 Maine Coon cats with severe HCM because
of a mutation (A31P) in the myosin-binding protein C
(MYBPC3) gene have increased expression of P-selectin,
platelet-derived microvesicles (PMVs), and platelet–
endothelial cell adhesion molecule-1.11 This suggested
that platelets might play a prominent role in the devel-
opment of the hypercoagulable state in feline HCM.
Clopidogrel, an antiplatelet drug, effectively inhibits
ADP-induced platelet aggregation in healthy cats.12,13
Here, we sought to determine whether clopidogrel
would be a logical treatment option in cats with per-
ceived risk of ATE.3,14 In human patients, clopidogrel
is a key component of antithrombotic treatment in
patients with acute ischemic stroke and coronary stent
implantation.15–17 However, substantial interindividual
variability exists and resistance to clopidogrel is
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associated with recurrent thrombosis and increased
morbidity.18 Although clopidogrel is commonly pre-
scribed to cats with ATE, little is known regarding its
effects on platelet activation and response variability.
The primary aim of this study was to evaluate the
response of feline platelets to clopidogrel and to charac-
terize variability in response to clopidogrel. The sec-
ondary aim of this study was to characterize platelet
activation and aggregation in cats homozygous for the
MYBPC3 A31P mutation before development of the
recognized phenotype of HCM. We hypothesized that
cats homozygous (HO) for the MYBPC3 A31P muta-
tion would have hyper-reactive platelets compared to
wild-type (WT) cats without the A31P mutation. We
also hypothesized that clopidogrel would attenuate pla-
telet sensitivity to ADP and that cats would exhibit a
highly variable response to clopidogrel treatment.
Materials and Method
Animals
The study protocol was approved by the Institutional
Animal Care and Use Committee at the University of
California, Davis. Fourteen cats were selected from a
newly established colony of Maine Coon/outbred mixed
domestic cats. Eight cats homozygous (HO) for A31P
mutation in the MYPBC3 gene and 6 wild-type (WT)
cats without the A31P mutation were studied. Cats were
between 12 and 44 months (median 18.5 months) of
age. As part of a separate and ongoing longitudinal
study, cardiac echocardiography was assessed for all 14
cats within 2 months before the start of this study.
None of the cats had echocardiographic evidence of
HCM at the time of the study, and all were considered
clinically healthy. Cats were observed for adverse reac-
tions to clopidogrel such as vomiting, inappetence, diar-
rhea, weight loss, and bleeding diathesis. On rare
occasions, blood samples from cats were not included
in portions of the study, as sample clotting and inade-
quate volume of platelet rich plasma (PRP) prevented
evaluation. If either blood samples taken before or after
clopidogrel were clotted, data from that animal were
not included in this portion of the study.
Each cat received 18.75 mg clopidogrel PO for
14 days. Blood was collected on day 0 (1 day before
clopidogrel administration) and day 15 (approximately
12 hours after the last clopidogrel dose was adminis-
tered). Complete blood counts were obtained using an
automated analyzer.a All cats were sedated with a com-
bination of acepromazine (0.05 mg/kg IM) and butor-
phanol (0.2 mg/kg IM) before venipuncture. Additional
doses of acepromazine, butorphanol, or both were
administered if required. Blood was drawn from the
medial saphenous vein using a 21-gauge butterfly needle
set, and 8 ml of blood was collected into 3.2% triso-
dium citrate tubes.
Response to clopidogrel was characterized based on
the percentage of change of ADP-induced platelet
aggregation (ADP-Ag) before and after the 14-day
clopidogrel treatment.16 Subjects with ≤10% inhibition
of ADP-Ag after clopidogrel treatment were classified
as nonresponders. Cats with >10% inhibition of ADP-
Ag after clopidogrel treatment were considered
responders.
Generation of Platelet-Rich Plasma
Citrated whole blood was transferred to polypropy-
lene tubes and diluted (1 : 5) with Tyrodes–HEPES buf-
fer lacking divalent cations but containing 5 mM
dextrose (37°C).19 PRP was generated by centrifugation
at 200 9 g for 5 minutes at 25–27°C.
Flow Cytometry
PRP platelet count was adjusted to 1 9 107/mL with
Tyrodes–HEPES buffer. Platelets were either unstimu-
lated (resting) or stimulated (activated) with 20 lM
ADPb and incubated for 15 minutes (37°C) before the
addition of antibodies. Samples were incubated with
monoclonal antibodies to CD62Pc and biotinylated
monoclonal antibodies to CD41bd at a final dilution of
1 : 100, respectively, for 45 minutes at 37°C. Samples
were then labeled with streptavidin conjugated to Alexa
633e (30 minutes) and fixed in 1% paraformaldehydef in
Tyrodes–HEPES buffer.
Flow cytometry was performed using a 5-color flow
cytometer.g Anti-mouse compensation beadsh and mon-
oclonal mouse immunoglobulin G1 kappa conjugated
to matched experimental fluorochromesi were used for
compensation controls. Platelets were identified by for-
ward and side scatter properties and by 0.9 lm and
3 lm calibration beads. For the identification of
CD62P (P-selectin) and CD41b (a2b subunit of the
major platelet integrin, a2bb3a)-positive events within
the platelet gate, gating boundaries were identified by
the use of fluorescence-minus-one controls.
Platelet-derived microvesicles (PMVs) were identified
as previously described by Robert et al.20 and Tablin
et al.11 Briefly, the microvesicle gate was determined by
the use of 0.5 lm and 3 lm calibration beads.j PMVs
were quantified by dividing the number of CD41b-
positive events by the total number of events within the
microvesicle gate and expressed as percentages. Flow
cytometry data were analyzed by commercially available
software.k
Western Blot Analyses of Intracellular
Phosphorylation of Vasodilator-Stimulated
Phosphoprotein (VASP)
Phosphorylation of the intracellular protein, VASP,
was quantified by Western blot analysis using affinity-
purified polyclonal antibodies. PRP from homozygous
and wild-type cats was generated as described above
and diluted with Tyrodes–HEPES buffer to a final pla-
telet concentration of 1 9 108/mL. Samples were incu-
bated with ADP (20 lM), prostaglandin E1 (PGE1)
(10 lM), or a combination of ADP (20 lM) and PGE1
(10 lM) [all incubations for 10 minutes, 37°C]. Unstim-
ulated samples served as the resting control population
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whereas PGE1-induced VASP phosphorylation served
as the positive control population. Samples were then
lysed in La€emmli buffer21 with antiproteases and
antiphosphatases (leupeptin, pepstatin, trypsin inhibitor
soybean, AESBSF, sodium orthovanadate, EDTA)l
(aproptinin and sodium fluoride)m and stored at 80°C
until further analysis.
Samples were evaluated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to nitrocellulose membranes. Membranes
were stained with Ponceau S (0.1%) to confirm equal
and adequate protein transfer. Membranes were
blocked with 3% gelatin at 37°C. Affinity-purified anti-
bodies were used to detect phosphorylation of serine
239 (pVASP)n and total VASP.o These antibodies were
chosen based upon high sequence homology when eval-
uated against the published feline VASP protein
(XP_006941169). Amino acid sequences of pVASP and
VASP antibodies were highly homologous (100% posi-
tive with 0 gaps, respectively) when compared to the
published feline VASP protein sequence as determined
by the Basic Local Alignment Search Tool, BLAST.22
Blots were washed 4 times and probed with anti-goat
antibodies conjugated to horseradish peroxidase
(1 : 50,000 dilution in 1% gelatin) (1 hour 37°C) and
treated with a chemiluminescent substrate. Blots were
imaged with a commercial imaging systemp and densito-
metry quantified using commercially available soft-
ware.q Immunoblotting and imaging for pVASP were
performed first followed by stripping of primary and
secondary antibodies using commercially available strip-
ping buffer.r To confirm specificity of antibody binding
after stripping, blots were incubated with secondary
antibodies against host animal (goat) in which the pri-
mary antibody was generated. Blots that showed no
residual antibody, as judged by the lack of secondary
antibody labeling in the absence of primary antibody,
were probed for total VASP on the same membrane.
Results were expressed as average optical density
(ODu/mm2) within chemiluminescent bands. Relative
phosphorylation of VASP was determined by the ratio
of average optical densities of pVASP to VASP
(pVASP:VASP). The nonphosphorylated VASP served
as an internal loading control.
The ability of ADP to inhibit PGE1-induced phos-
phorylation of VASP was evaluated by ADP receptor
response index (ARRI) using the following calculation
as previously described by Hezard et al.23:
RIð%Þ ¼ ðODPGE1 ODPGE1þADPÞ=ðODPGE1Þ  100
Optical Aggregometry
PRP from citrated whole blood was prepared as
described above and diluted with Tyrodes–HEPES to a
final platelet count of 1.5 9 108/mL, and aggregation
measured by optical aggregometry.s Testing was per-
formed within 60 minutes after venipuncture. Aggrega-
tion was recorded for 1 minute before the addition of
ADP (40 lM) or thrombint (bovine-derived, 1 Unit/mL),
and the reaction runs for 5 additional minutes.
Thrombin-induced aggregation (Throm-Ag) served as
positive control. Percentage of maximal aggregation (am-
plitude) was calculated using commercially available
software.u
Response to Clopidogrel
The response of each cat to clopidogrel treatment
was categorized based on previously established criteria
for human patients.16 Percent inhibition was calculated
by the following formula:
ðADP-AgPRETREATMENT
ADP-AgPOSTTREATMENTÞ=ADP-AgPRETREATMENT
 100
Statistical Analysis
Normality was tested using the Shapiro–Wilk normal-
ity test. Normally distributed and paired data were ana-
lyzed using t-test. Nonparametric and paired data were
analyzed using the Wilcoxon signed-rank test. Pearson
correlation coefficients were calculated to describe the
agreement between different platelet function assess-
ments. Interindividual variability was calculated as the
ratio between the standard deviation of a group and its
mean (coefficient of variation). Parametric data were
presented as mean  standard deviation, and nonpara-
metric data were presented as median and interquartile
range (IQR). Statistical analysis was performed using
commercially available software.v An a priori alpha of
P < .05 was considered statistically significant.
Results
Flow Cytometry
Before clopidogrel treatment, ADP stimulation
resulted in a significantly higher percentage of P-selec-
tin-positive platelets and P-selectin mean fluorescence
intensity (MFI) as compared to unstimulated (resting)
platelets (Fig 1). Mean percentages of P-selectin-positive
platelets were 35.53  21.42% in resting platelets and
46.75  6.27% in ADP-activated platelets. ADP stimu-
lation resulted in a significant increase in P-selectin
MFI (from 4791  2598 to 7412  4702) (P = .0067).
However, after 14 days of clopidogrel treatment, no sig-
nificant differences in percentage of P-selectin-positive
platelets and P-selectin MFI were identified between
ADP-stimulated activation and resting platelets
(P = .87, P = .52, respectively) (Fig 2). Mean percent-
ages of P-selectin-positive platelets were 50.49 
21.85% in resting platelets and 51.55  20.39% in
ADP-activated platelets. Mean P-selectin MFIs were
453  1272 (resting) and 4350  1519 (activated).
Overall, in cats, HO for A31P mutation of the
MYPBC3 gene, ADP-induced P-selectin expression
(P-selectin MFI and percentage of P-selectin-positive
platelets) was significantly higher as compared to resting
platelets (P = .0095, P = .016). Before clopidogrel treat-
ment, all cats HO for A31P mutation, but one, had an
increase in P-selectin-positive platelets after ADP
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stimulation. Median percentages of P-selectin-positive
platelets in resting and activated platelets were 35.55%
(IQR: 18.58–48.55) and 58.90% (IQR: 24.85–69.90), as
shown next to the data points (Fig 3A). Not all HO
cats had elevated P-selectin MFI after ADP stimula-
tion but 4 of 8 cats had substantial increase. When
compared to resting platelets, ADP activation resulted
in a significant increase in median platelet MFI [from
3215 (IQR: 2347–5904) to 5758 (IQR: 2590–12197)] in
HO cats (P = .035) (Fig 3B). The response to ADP
was variable in WT cats, with platelets from 2 of 6
cats showing minimal to no response to ADP (Fig 3C
and D). Median percentages of P-selectin-positive pla-
telets were 34.30% (IQR: 14.27–64.35) and 44.70%
(IQR: 15.20–71.08) in resting and activated platelets,
respectively. No significant increase in P-selectin-posi-
tive platelets was found when compared to resting pla-
telets (P = .69). All WT cats, except one, showed
increase in P-selectin MFI after ADP stimulation. No
significant increase in median P-selectin MFI [resting:
5362 (IQR: 3195–8997), activated: 7755 (IQR: 4127–
Fig 1. Flow cytometric analysis of P-selectin expression in 14 cats
before clopidogrel treatment. (A) Representative histogram of rest-
ing platelets (blue) and ADP-activated platelets (red) indicating
the significant increase in platelet P-selectin expression before
clopidogrel treatment. ADP-induced stimulation resulted in signifi-
cant increase of percentage (%) in P-selectin-positive platelets
(B) and P-selectin MFI (C) as compared to resting platelets. The
bolded line represents the mean, and the lower and upper lines
represent the standard deviations.
Fig 2. Flow cytometric analysis of P-selectin expression in 14 cats
after clopidogrel treatment (day 15). (A) Representative histogram
of resting platelets (blue) and ADP-activated platelets (red) after
clopidogrel treatment. After 14 days of clopidogrel treatment, no
significant changes in P-selectin expression were seen in resting
(blue) and ADP-activated platelets (red). ADP-induced stimulation
did not result in a significant increase of percentage (%) of P-selec-
tin-positive platelets (B) and P-selectin MFI (C) as compared to
resting platelets. The bolded line represents the mean and the
upper and lower lines represent the standard deviations.
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12,650)] was found after ADP-induced activation
(P = .16).
After 14 days of clopidogrel treatment, no significant
differences in P-selectin-positive platelets and P-selectin
MFI were found in resting and activated platelets in
either HO or WT cats (Fig 4). ADP stimulation did not
result in significant increase in percentage (%) of
P-selectin platelets in either HO (P = .84) or WT
(P = .44) cats compared to resting platelets (Fig 4A). In
HO cats, median P-selectin-positive platelets were
47.10% (IQR: 37.83–65.28) and 43.35% (IQR: 39.60–
64.08) in resting and activated platelets, respectively. In
WT cats, median P-selectin-positive platelets were
58.10% (IQR: 30.18–71.80) (resting) platelets and
52.40% (IQR: 32.42–76.10) (activated). ADP stimula-
tion did not result in significant increase in P-selectin
MFI compared to resting platelets in either HO
(P = .73) or WT (P = .44) cats. In HO cats, median
P-selectin MFIs were 4353 (IQR: 3061–5039) (resting)
and 4026 (IQR: 2976–5449) (activated). In WT cats,
median P-selectin MFIs were 4633 (IQR: 3820–5805)
(resting) and 4600 (IQR: 3915–5480) (activated).
Before clopidogrel treatment, mean PMVs were
25.12  16.07% (resting) and 20.42  17.46% (acti-
vated) in all cats. After clopidogrel treatment,
mean PMVs were 15.34  18.12% (resting) and
17.42  21.40% (activated). ADP stimulation did not
result in significant differences in the number of PMVs
compared to resting platelets (P = .39), nor were there
any differences compared to postclopidogrel resting
samples (P = .54).
When examining PMVs based on genotype, ADP stim-
ulation resulted in an increase in PMVs [5.67% (IQR:
1.47–36.90) to 10.67% (IQR: 2.28–44.75)] before clopido-
grel treatment in cats HO for A31P mutation, but the dif-
ference was not statistically significant (P = .25). In WT
cats, PMVs did not significantly increase after stimula-
tion with ADP [resting: 6.45% (IQR: 3.37–19.48), acti-
vated: 3.43% (IQR: 2.25–22.80) before treatment
(P = .44). After clopidogrel treatment, no significant dif-
ferences in PMVs were noted between resting (27.45%,
IQR: 8.14–47.65) and activated (23.70%, IQR: 11.19–
32.45) in HO cats. Similarly, no differences in PMVs were
found in WT cats [resting: 23.75% (IQR: 15.47–29.43),
activated: 13.35% (IQR: 4.96–20.48)] (P = .43).
Optical Aggregometry
The amplitude of ADP-Ag was not significantly dif-
ferent from Throm-Ag on day 0 (P = .093). The
mean maximum amplitudes (MA) of ADP-Ag and
Throm-Ag were 51  24.25% and 61.92  19.48%,
respectively. However, after 14 days of clopidogrel
treatment, the mean MA of ADP-Ag (8.54  4.72%)
was significantly lower than Throm-Ag (56.25 
28.33%) in all cats (P = .0001). ADP-Ag was signifi-
cantly higher on day 0 than on day 15 (P = .0002).
Throm-Ag on days 0 and 15 was not significantly dif-
ferent (P = .68) (Fig 5).
Before clopidogrel treatment, ADP-Ag [median MA:
47.50% (IQR: 21.25–73)] was not significantly different
from Throm-Ag [median MA: 63% (IQR: 34.00–76)]
in HO cats (P = .45). Similarly in WT cats, ADP-Ag
[median MA: 68% (IQR: 41–71)] was not different
from Throm-Ag [median MA: 71% (IQR: 60–82)] in
WT cats (P = .31). On day 15, significant reduction in
ADP-Ag [median MA: 9.50% (IQR: 6.25–10.75)] was
found in HO cats when compared to Throm-Ag [me-
dian MA: 47.50% (IQR: 34.00–76)] in HO cats
(P = .016). In WT cats, ADP-Ag [median MA: 9.00%
(3.00–14.50)] was significantly lower than Throm-Ag
[median MA: 65% (IQR: 37.00–79.50)] (P = .040). As
Fig 3. Line plots illustrating the changes in platelet P-selectin
expression in resting and ADP-stimulated platelets from HO
(A, B) and WT (C, D) cats before 14 days of clopidogrel treat-
ment. Medians and interquartile ranges are shown beside the line
plots.
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expected, clopidogrel treatment did not lead to a signif-
icant decrease in the MA of Throm-Ag in either HO
or WT cats (P = .750, P = .438, respectively). ADP-Ag
amplitude in HO cats was not significantly different
from ADP-Ag in WT cats on day 15 (P = .65).
Because of inadequate volume of PRP on day 0 and
sample clotting on day 15 in a single cat (WT), no
optical aggregometry data were available from that
subject.
Platelet VASP Phosphorylation and ADP Receptor
Response Index
Two cats (1 WT and 1 HO) were excluded from Wes-
tern blot analyses because of inadequate PRP volume
on day 0.
Representative Western blots are shown in Figure 6.
Before clopidogrel treatment, the mean relative pVASP
intensities of PGE1-treated platelets (0.54  0.24)
were not significantly different from either resting
(0.58  0.32) or ADP-treated (0.46  0.21) platelets
(P = .44, P = .21, respectively). However, before clopi-
dogrel treatment, relative pVASP was significantly
lower in PGE1+ADP-treated platelets (0.43  0.20)
than in platelets treated with PGE1 alone (P = .049)
(Fig 7A).
After 14 days of clopidogrel treatment, relative
pVASP in platelets treated with PGE1 and ADP was
not significantly different from platelets treated with
PGE1 alone (P = .62) (Fig 7A). Mean relative pVASP
was not significantly different among PGE1-treated
(0.55  0.22), resting (0.37  0.25), and ADP-treated
(0.37  0.18) platelets (P = .21, P = .21, respectively).
ARRI after clopidogrel treatment was significantly
lower than ARRI before treatment (P = .017) (Fig 7B).
The median ARRIs were 24.13% (IQR: 12.46–35.50)
Fig 4. Flow cytometric analysis of platelet P-selectin expression
from HO and WT cats after 14 days of clopidogrel treatment.
ADP-induced stimulation did not result in significant increase in
percentage (%) of P-selectin-positive platelets (A) and P-selectin
MFI (B).
Fig 5. Percentages (%) of maximum aggregation measured by
optical aggregometry in 13 cats before (day 0) and after clopido-
grel (day 15). The bolded line represents the mean, and lower and
upper lines represent the standard deviations.
Fig 6. Representative Western blot analysis of platelet vasodila-
tor-stimulated phosphoprotein (VASP) phosphorylation in 3 differ-
ent cats. (A) The molecular weight of total VASP is approximately
at 46 kDa (Arrow head). Phosphorylation of serine 239 of VASP
(pVASP) caused the protein to migrate to 50 kDa (black arrow).
Immunoblots were shown to demonstrate the differences in molec-
ular weight. (B) PGE1 serves as a positive control, as the rise in
cAMP after PGE1 treatment results in strong pVASP expression.
Platelets were either unstimulated/resting or treated with 20 lM
ADP, 10 lM PGE1 (positive control) or a combination of 20 lM
ADP and 10 lM PGE1. Before clopidogrel treatment, ADP inhib-
ited pVASP and partially inhibited PGE1-induced pVASP.
(C) After clopidogrel treatment, irreversible antagonism of P2Y12
abolished the effect of ADP on PGE1-induced pVASP. The degree
of VASP phosphorylation in resting and ADP-treated platelets
also was similar to positive control.
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and 11.30% (IQR: 7.383 to 23.27) on day 0 and day
15, respectively.
Response to Clopidogrel
None of the cats displayed clinical signs suggestive of
adverse reactions to clopidogrel. Of 13 samples avail-
able for optical aggregometry, 2 nonresponders and 11
responders to clopidogrel treatment were identified
based on platelet response to ADP-Ag. Both nonre-
sponders had low ADP-Ag before and after clopidogrel
treatment (1–3 and 18–20%). The median percent
inhibition among responders was 86.21% (IQR: 81.82–
88.71). ADP stimulation also did not result in a sig-
nificant increase in percent-positive P-selectin when
compared to resting platelets of responders. The two
nonresponders showed variable increases in P-selectin
MFI despite clopidogrel treatment whereas virtually all
responders, with one exception, had decreased P-selectin
expression (Fig 8). ARRI was also significantly
decreased in responders after treatment (P = .020).
Nonresponders also were observed to have reduced
ARRI after clopidogrel treatment. Within the
population of responders, 7 cats were HO and 4 cats
were WT.
Overall, interindividual variability in response to
clopidogrel treatment was high, ranging from 34.92 to
100% depending on the tests used to assess clopidogrel
response. Measurement of ARRI using Western blot
analysis had the highest interindividual variability
(CVARRI = 26.9) whereas flow cytometric detection of
P-selectin expression had the lowest interindividual vari-
ability (CVMFI = 0.35, CV% = 0.40). ADP-Ag using
OA had a CV of 0.55.
Discussion
In the absence of HCM, cats HO for the A31P muta-
tion of the MYPBC3 gene had reactive platelets as mea-
sured by increased ADP-induced P-selectin expression
relative to the more variable response seen in WT cats.
Here, we showed that 14 days of clopidogrel treatment
attenuated ADP-mediated P-selectin expression on pla-
telets from either HO or WT cats, illustrating the potent
antiplatelet effects of clopidogrel in apparently healthy
cats with or without the A31P mutation. A dosage of
18.75 mg, PO, given every 24 hours for 14 days also
resulted in significant inhibition of ADP-induced aggre-
gation and increase in pVASP.
Once metabolized in the liver, the active metabolite
of clopidogrel covalently binds with P2Y12, one of two
platelet ADP receptors. P2Y12 is a purinergic class of
G-protein-coupled receptor and clopidogrel abolishes
ADP-mediated downstream signaling by inhibiting
inside-out activation of the platelet integrin, a2bb3,
which is critical for platelet aggregation.24,25 The
profound inhibition of platelet aggregation after clopi-
dogrel treatment observed in this study indicates that a
Fig 7. (A) Relative phosphorylation of vasodilator-stimulated
phosphoprotein (VASP) quantified by Western blot analysis in
platelets from 12 cats before (day 0) and after 14 days (day 15) of
clopidogrel treatment. (B) ADP receptor response index (ARRI) in
12 cats before (day 0) and after 14 days (day 15) of clopidogrel
treatment. The bolded line represents the mean, and the upper and
lower lines represent the interquartile range.
Fig 8. Line plots illustrating the changes in P-selectin expression
before and after 14 days of clopidogrel treatment in 11 responders
and 2 nonresponders. On day 15, the differences in P-selectin mean
MFI between resting and ADP-stimulated platelets in nonrespon-
ders were higher than those on day 0. All responders but one had
an attenuated response to ADP stimulation.
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similar mechanism of action likely occurs in feline
platelets.
P-selectin, an integral protein of the a-granule mem-
brane, is exposed on the platelet surface by fusion of
the a-granule membrane with plasma membrane.
Because fusion is necessary for platelet granule secre-
tion, surface expression of P-selectin serves as a useful
marker of ADP-induced platelet activation and a-gran-
ule secretion.26 Upon ADP stimulation, platelet P-selec-
tin expression in cats HO for the A31P mutation was
significantly upregulated. This finding further suggests
the conclusion that cats with genetic predisposition to
HCM have procoagulant platelets that predispose them
to intracardiac thrombi formation and increased risk
for ATE. Platelet P-selectin expression in this popula-
tion of cats was generally higher than previously
reported.11 The differences in results were likely because
of the use of different CD62P antibodies, in vitro acti-
vation from sample handing and centrifugation, age
and genetic differences between the studied populations.
In humans, platelet reactivity is associated with mortal-
ity because of myocardial infarction.27,28 Platelet reac-
tivity can be the result of platelet priming, a regulatory
mechanism that amplifies the platelet response to ago-
nists and, thus, contributes to thrombus formation and
growth.29 For that reason, neutralization of platelet
priming presents a novel treatment paradigm for throm-
bus prevention, and thus, further studies in HCM cats
are warranted.
The attenuated ADP-induced P-selectin expression by
clopidogrel treatment suggests additional benefits of this
drug in ATE cats. Because the binding of P-selectin to
its ligand, P-selectin glycoprotein ligand-1, facilitates
recruitment of leukocytes to thrombi and enhances
platelet–leukocyte interaction and tissue factor expres-
sion by capturing leukocyte-derived microvesicles, inhi-
bition of this interaction may further reduce the
progression of thrombosis and inflammation.30–32 Spon-
taneous echocardiographic contrast, a swirling blood
flow pattern associated with blood stasis in the LAA, is
a common finding and a suggested predictor of throm-
boembolic outcomes in feline HCM.33–35 A study utiliz-
ing direct analysis of left atrial blood showed that
human patients with spontaneous echocardiographic
contrast had increased platelet P-selectin expression and
platelet–leukocyte aggregates.36 However, it remains
unknown whether elevated P-selectin expression in cats
predisposed to HCM could be associated with increased
platelet–neutrophil interaction and spontaneous
echocardiographic contrast in the LAA. Considering
that several ex vivo studies have demonstrated the effec-
tiveness of clopidogrel in attenuating platelet–leukocyte
adhesion and platelet-dependent leukocyte activation,
further studies are required to investigate the effects of
clopidogrel on platelet–leukocyte interactions in
cats.32,37,38
Clopidogrel did not affect ADP-mediated expression
of PMVs in the present study. Studies on human plate-
lets have shown that P2Y12 receptors are involved in
PMV formation, loss of phospholipid asymmetry and
externalization of phophatidylserine.39,40 There are
several reasons that may explain the negative results
found in this study. Firstly, although P2Y12 potentiates
PMV formation, ADP, when used alone, is considered
a weak agonist and may lack the ability to induce PMV
formation in vitro.41 Furthermore, the use of citrate as
an anticoagulant might have inhibited PMV formation
because low extracellular calcium concentration pre-
vents activation of calcium-dependent calpain, which
facilitates PMV formation by degrading structural pro-
teins such as actin-binding protein.37 Because cats with
severe HCM were demonstrated to have a significant
increase in PMV, it is also possible that PMV formation
could be associated with disease severity and that the
lack of clinical HCM precluded any significant changes
in PMV formation.11
In human platelets, the binding of ADP to P2Y12
activates the G-protein, Gi2a, which inhibits adenyl
cyclase and reduces cyclic AMP (cAMP). cAMP, an
important mediator of platelet reactivity, stimulates
cAMP-dependent protein kinase A, which phosphory-
lates a number of substrate proteins responsible for pla-
telet inhibition.42 Activation of platelets by ADP,
therefore, decreases the activation of protein kinase A
resulting in decreased phosphorylation of VASP. The
active metabolite of clopidogrel irreversibly binds to
P2Y12 and abolishes the downstream signaling causing
increases in cAMP and pVASP. Because PGE1 increases
intracellular cAMP and causes subsequent VASP phos-
phorylation, PGE1-treated platelets served as the posi-
tive controls in this study. By treating platelets with
both ADP and PGE1, the difference in pVASP mea-
sured as ARRI served as an indirect marker of P2Y12
inhibition. In agreement with human studies, cats had
significantly lower ARRI after 14 days of clopidogrel
treatment. In addition, relative pVASP was similar in
PGE1-treated and resting platelets after clopidogrel
treatment. Although the platelet ADP receptors and G
proteins have not been characterized in feline platelets,
the results of the current study suggest that there is a
similar intracellular signaling mechanism of action.
In the present study, no differences in relative
pVASP were found in resting, ADP-treated and PGE1-
treated platelets. A possible explanation for this find-
ing is that other pathways may have influenced VASP
phosphorylation in feline platelets. For instance, phos-
phorylation of VASP is influenced by cyclic GMP-
dependent protein kinase (PKG) that is independent of
P2Y12 inhibition in human platelets.
43 In addition,
processing of samples and preparation of PRP could
exert mechanical stress on platelets and facilitate
platelet–platelet interaction causing in vitro activation
and release of endogenous ADP, which could influence
pVASP.44,45
The present study showed an important degree of
interindividual variability in response to a defined dose
of clopidogrel suggesting that some cats may not be
adequately protected from ATE. This heterogeneous
response to clopidogrel is well described in human
beings.18,46,47 Genetic polymorphisms of CYP2C19, a
key enzyme in the biotransformation of clopidogrel, are
known to affect pharmacodynamics and
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pharmacokinetics of clopidogrel as low responders often
carry low-function CYP2C19 alleles.48,49 Other mecha-
nisms of variation include drug interaction with proton
pump inhibitors and P2Y12 receptor gene polymor-
phisms that influence not only the ADP responsiveness
but also the extent of platelet inhibition by clopido-
grel.50,51 Interindividual variability may also reflect the
sensitivity and variability of the techniques used to
assess platelet activation. The large variations and
ranges of ARRIs likely reflected the semiquantitative
nature of the data generated by Western Blot analysis.
Similar to previously published human studies, a pro-
portion of cats (2/13) did not respond to clopidogrel.
Interestingly, platelets from both nonresponder cats had
diminished response to ADP on OA and flow cytometry
but maintained normal response to thrombin before
and after clopidogrel treatment. Although both flow
cytometry and OA identified nonresponders to ADP,
they do not examine the same cellular events that occur
after ADP stimulation and, therefore, may have differ-
ent specificities in assessing clopidogrel responsiveness.52
Nonresponders in this case would be more appropri-
ately defined as nonresponders to ADP because no
residual platelet activation to ADP was found after
clopidogrel treatment. This suggests that cats in this
population may have P2Y12 receptor polymorphisms,
which will require genetic studies for confirmation.
Because clopidogrel resistance is associated with increa-
sed morbidities in human patients such as stent throm-
bosis, recurrent ischemic cardiovascular events and
myocardial infarction, further research into the mecha-
nism and clinical significance of clopidogrel resistance
in HCM cats is needed.46,53
The present study has several limitations. Firstly, the
definition of clopidogrel responsiveness in this study is
empiric. Because no information on this subject exists
in veterinary medicine, we used guidelines previously
established by Gurbel et al.18 who used a similar con-
centration of ADP in OA to assess clopidogrel respon-
siveness in patients undergoing percutaneous coronary
intervention. In addition, cut-offs generated in most
large-scale clinical trials are highly dependent on the
subset of patients studied. It should be noted that the
cut-offs used in this study were solely for categorizing
the degree of clopidogrel response and should not be
used to guide clinical decisions. Future clinical trials
examining clopidogrel responses in a large population
of HCM or ATE cats are needed. It is unknown at this
stage whether the progression of HCM may affect plate-
let reactivity in cats. Additionally, the higher concentra-
tion of ADP (40 lM) used in OA versus the 20 lM
concentrations used for flow cytometry and Western
blots is a limitation. Although there is evidence suggest-
ing that acepromazine may decrease platelet aggregation
in dogs, its effects on platelet function in cats are poorly
understood.54,55 Lastly, exclusion of subjects because of
sample clotting or inadequate volume of PRP may have
led to type I error.
In conclusion, our study shows that platelet activa-
tion and aggregation are significantly inhibited by
14 days of clopidogrel treatment. Platelets from cats
HO for the A31P mutation were more reactive than
control platelets which had a variable response to ADP.
Clopidogrel response variability was demonstrated in
cats by ADP-Ag, P-selectin expression and VASP phos-
phorylation suggesting that some cats are pharmacolog-
ically resistant to clopidogrel. ADP-Ag and flow
cytometry could be useful diagnostic tests in assessing
clopidogrel response in cats and should be further
investigated to optimize patient outcomes.
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